SCHEMBL4485080

SCHEMBL4485080

CC(C)(C)C(C(=O)N1CCN(c2ccc(Cl)c(Cl)c2)CC1)N(C(=O)C(F)(F)F)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 2/20 0.58
MAPT P10636 7/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
HTT P42858 5/20 0.45
LMNA P02545 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
RECQL P46063 2/20 0.45
MAPK1 P28482 3/20 0.44
RAB9A P51151 1/20 0.43
TP53 P04637 2/20 0.42
PANK3 Q9H999 1/20 0.42
NPY2R P49146 1/20 0.42
USP2 O75604 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
POLB P06746 1/20 0.41
TSHR P16473 2/20 0.41
ALDH1A1 P00352 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4485074 0.79 CCR1 (0.68) CCR1MAPTSMN1; SMN2HTTLMNA
SCHEMBL13606397 0.77 CCR1 (0.75) CCR1MAPTSMN1; SMN2HTTLMNA
SCHEMBL4500331 0.74 CCR1 (1.00) CCR1MAPTSMN1; SMN2HTTLMNA
SCHEMBL4500020 0.74 CCR1 (1.00) CCR1MAPTSMN1; SMN2HTTLMNA
SCHEMBL4491041 0.73 MAPT (0.58) CCR1MAPTSMN1; SMN2HTTLMNA
SCHEMBL4491038 0.73 MAPT (0.58) CCR1MAPTSMN1; SMN2HTTLMNA
SCHEMBL4493323 0.70 CCR1 (0.64) CCR1MAPTSMN1; SMN2HTTLMNA
SCHEMBL4493321 0.70 CCR1 (0.64) CCR1MAPTSMN1; SMN2HTTLMNA
SCHEMBL4508912 0.70 NPSR1 (0.45) CCR1MAPTSMN1; SMN2LMNAKMT2A
SCHEMBL4487677 0.70 CCR1 (0.61) CCR1MAPTSMN1; SMN2HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609664-B2 Piperazinyl derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB CO. (US) 2013-12-17 US disclosed
EP-1973880-B1 PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2013-08-07 EP disclosed
US-20090298845-A1 PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2009-12-03 US disclosed
US-7615556-B2 Piperazinyl derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-10 US disclosed
EP-1973880-A1 PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Brystol-Myers Squibb Company (US) 2008-10-01 EP disclosed
US-20070179148-A1 PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2007-08-02 US disclosed
WO-2007087585-A1 PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298845-A1 PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR2, CCR5, CCR1 CCR1 3/4885MAPT 4559/4885SMN1; SMN2 4822/4885
US-20070179148-A1 PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR2, CCR5, CCR1 CCR1 3/4885MAPT 4559/4885SMN1; SMN2 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.